10.75 (-%)
As of Nov 20, 2024
Source:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company. Our lead product candidate, FT218, is an investigational once-nightly, extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness (“EDS”) or cataplexy in adults with narcolepsy.
| Country | United States |
| Headquarters | dublin |
| Phone Number | 636-449-1830 |
| Industry | manufacturing |
| CEO | Gregory J. Divis |
| Website | www.avadel.com |